Furthermore, as an adaptor protein in SCF complex, SKP1 possesses a broad function in the cells, especially in normal cells; as the result, inhibition of the main downstream pathways, Hippo/YAP signaling, would be a feasible strategy to reduce the side-effect of anti-cancer treatment targeting SKP1. The gene discussed is SKP1; the disease is cancer.